Spain takes, on average, two years to approve a drug for a minority disease

There are 146 orphan drugs approved by the European Medicines Agency. Spain has only 81 in its catalogue. It has rejected funding for 25 and is studying 17 others. ondacero.es There are two main anxieties for those suffering from a so-called rare or minority disease and their families. One is to name the disease, and […]

22% of clinical trials underway in Spain seek new treatments for rare diseases

Research into new drugs for rare diseases has multiplied in recent years. In Spain, industry drives 90% of clinical trials for this type of disease. One out of every three drugs with a new active ingredient authorised in Europe in 2023 was an orphan drug On World Rare Disease Day, celebrated on 29 February, we […]

The Andalusian Regional Government and Farmaindustria will promote R&D&I in health with a special focus on the promotion of clinical trials.

In a press release, the Andalusian Regional Government highlights the joint commitment of both entities to continue advancing in the promotion of R&D&I, following the meeting of the Secretary General for Public Health and Health Research, Development and Innovation of the Regional Ministry of Health and Consumer Affairs, Isaac Túnez, with the Governing Council of […]

Europe calls latest cancer drugs “significant progress” for health

The European Medicines Agency has thus identified nine oncology approvals for 2023. The arrival of new treatments is directly linked to the pharmaceutical industry’s commitment to the fight against cancer. Survival in some tumour types now exceeds 90%. A new study by the Swedish Institute of Health Economics finds inequalities in access to screening, biomarkers […]

The Innovative Medicines Platform sets its roadmap for 2024 with the aim of turning Spain into a major biomedical innovation hub

The Technological Platform for Innovative Medicines – whose Coordination Committee is made up of 10 representatives from the pharmaceutical industry and 10 representatives from public research – defines its action plan for 2024 and debates advances and new developments in preclinical and clinical research and the use of data, among others. The Annual Conference of […]

Frank R. Lichtenberg, Professor at Columbia University: “Life expectancy of cancer patients in Spain has increased by almost three years in the last decade thanks to the use of innovative drugs”.

The US expert unpacked the data from his study on the relationship between pharmaceutical innovation and cancer mortality in Spain between 1999 and 2016 in a webinar organised by Farmaindustria. “The use of new cancer drugs in this period managed to reduce cancer deaths in Spain by almost 30%, more than 42,000 people,” said Lichtenberg. […]